COMMUNIQUÉS West-GlobeNewswire

Tilray Beverages Unveils New Fall Seasonal Craft Brews with Oktoberfest-Inspired Lineup
23/09/2025
ATLANTA, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a leading global lifestyle and consumer packaged goods company, is raising a stein to the season with a festive lineup of [...]
SEED Therapeutics Completes $30 Million Series A-3 Financing
23/09/2025
KING OF PRUSSIA, Pa., Sept. 23, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers [...]
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
23/09/2025
FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized as [...]
Transpire Bio’s ANDA for Generic Breo® Ellipta® Accepted for Filing By the U.S. FDA
23/09/2025
SUNRISE, Fla., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Transpire Bio, an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announces [...]
Microbix Assisting EMQN with Second Genetic-Test EQA Program
23/09/2025
Helping Ensure Appropriate Dosing of Widely-Used Anti-Clotting Drugs MISSISSAUGA, Ontario and MANCHESTER, United Kingdom, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix [...]
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22
23/09/2025
Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 First disclosure of a novel mechanism of action for the degradation of [...]
atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression
23/09/2025
Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with treatment-resistant depression and demonstrated rapid, clinically meaningful and durable [...]
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
23/09/2025
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for [...]
Altimmune to Participate in Two Upcoming Investor Conferences
23/09/2025
GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, [...]
Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025
23/09/2025
BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients [...]
Atsena Therapeutics Announces Dosing Complete for Adults in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis
23/09/2025
Pediatric dosing expected to begin in Q4 2025 Pivotal cohort expected to begin enrolling in Q1 2026 BLA submission anticipated in early 2028 Part A results demonstrated efficacy and safety; ATSN-201 on track to be first [...]
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
23/09/2025
BETHESDA, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Umoja Biopharma Named One of 2025’s Most Promising Biotech Companies by Endpoints News and Fierce Biotech
23/09/2025
SEATTLE, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced its recognition by both [...]
Des défis ambitieux, des retombées majeures: La Fondation de la famille Weston attribue 20 millions de dollars pour des projets de recherche de pointe en matière de santé, à l’avant-garde de l’innovation
23/09/2025
L’Université McGill et l’Université de l’Alberta reçoivent chacune 10 millions de dollars pour poursuivre des recherches de pointe susceptibles de transformer la santé des Canadiens. TORONTO, 23 sept. 2025 (GLOBE [...]
High Stakes, High Impact: $20 million from the Weston Family Foundation awarded to cutting-edge health research projects at the forefront of innovation
23/09/2025
McGill University and University of Alberta each awarded $10M to pursue bold research with transformational potential to redefine health outcomes for Canadians TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- In a move to [...]
PROPHASE LABS, INC. ANNOUNCES COMPLETION OF IMPORTANT NEXT STEP FOR CROWN MEDICAL COLLECTIONS $50 MILLION A/R INITIATIVE
23/09/2025
COVID-19 TESTING LABORATORY SUBSIDIARIES FILE FOR BANKRUPCTY PROTECTION UNIONDALE, NY, Sept. 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, [...]
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
23/09/2025
Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segment BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” [...]
Vanderbilt Report: Full Alliance Group helps Power Hypochlorous Acid’s Breakout from Hospitals to the Global Consumer Market
23/09/2025
BRISTOL, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Once relegated to the back rooms of hospitals, hypochlorous acid (HOCl) is rapidly becoming one of the most disruptive platform chemicals of the decade and Full [...]
Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference
23/09/2025
CUPERTINO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]

Pages